Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
BUSINESS ACCOUNT
Sign up for a business account to:
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
Get access to other exclusive features
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Oscar Haffen Lamm
- Oscar Haffen Lamm
BioInvent: Updated ph2a data on BI-1808 in CTCL shared at EHA
At EHA, BioInvent shared updated phase 2a data on BI-1808 in CTCL. Among 9 evaluable CTCL patients (7 SS, 2 MF), results showed 1 CR (SS), 3 PRs (2 SS, 1 MF), and 5 SDs - resulting in an ORR of c. 45% and a DCR of 100%. In PTCL, 2 patients were evaluable with 1 PR and 1 SD. On the safety front, all
Cédric Rossi
- Cédric Rossi
BIC: new CEO found
Yesterday evening, BIC announced the appointment of Rob Versloot as CEO, effective 15th September. Rob Versloot has 30+ years of experience in the FMCG sector, including Danone and Hero Group where he was appointed as CEO in 2012. The choice of an "external" profile, rare at BIC, does not surprise
Cédric Rossi
- Cédric Rossi
Inditex: normalised, not neutralised (cancel & replace)
Whereas Q1 results broadly met expectations, current trading was again underwhelming, with sales from 1st May to 9th June up 6% FX-n (vs. CSSe c.+7%), reflecting volatile demand and a tough comp base. We have trimmed our FY25 estimates by 3% to account for the ongoing normalisation phase and a more
Clément Genelot
- Clément Genelot
Fnac Darty: services, services and more services on the 2030 menu
Continuing on from its previous plan, Fnac Darty has presented a 2030 strategic plan skewed towards the development of subscription services and the catch-up of Unieuro. We welcome this focus on services in a saturated market where growth and profitability can no longer rely on devices, but expect
Oscar Haffen Lamm
- Oscar Haffen Lamm
BioInvent: BI-1206 & pembro combo enters phase 2a, targeting 1L NSCLC ...
BioInvent has completed the phase 1 portion of its trial evaluating BI-1206 in combination with pembrolizumab across solid tumors and will initiate the phase 2a expansion, targeting 1L NSCLC and 1L uveal melanoma (UM), with enrollment expected in H2 2025. Initial data readouts are anticipated in 20
Gregory Ramirez
- Gregory Ramirez
Thibault Morel
- Thibault Morel
Cedric Rossi
- Cedric Rossi
HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...
HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%
Clement Genelot
- Clement Genelot